Avantor Results Presentation Deck

Key highlights Li Strong business momentum continued in Q4 Exceeded guidance across all key financial performance metrics Core business growth led by Biopharma and ATAM COVID-19 revenues in line with guidance Significant margin expansion and adjusted EPS and FCF growth - Executing on our growth strategy Closed acquisition of Masterflex, expanding our proprietary single-use offering for critical bioproduction workflows Continued investment in manufacturing capacity and capabilities Launched LC/MS consumables from Agilent Technologies to enhance workflow solutions - Looking ahead Healthy end markets and strong order books Initial 2022 guidance builds on long-term growth framework. Continued focus on execution, integration and deleveraging - avantor™ 3

View entire presentation